文献速递药物相互作用

利福平弱与强CYP3A诱导对五种孕激素及炔雌醇药代动力学的影响:与咪达唑仑比较

The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam.
PubMed 文献 · Clin Pharmacol Ther · 2020-05-11

一项随机药物相互作用研究在绝经后女性中比较利福平弱诱导(10 mg/日)与强诱导(600 mg/日)对左炔诺孕酮、炔诺酮、去氧孕烯、地诺孕素单方及屈螺酮联合炔雌醇药代动力学的影响,以咪达唑仑为探针。弱诱导使咪达唑仑暴露平均降低46%,孕激素暴露平均降低15-37%;强诱导使咪达唑仑暴露平均降低86%,孕激素暴露平均降低57-90%。提示弱CYP3A诱导剂对孕激素暴露影响较小,可能需重新审视口服避孕药临床推荐。

要点

  • 弱CYP3A诱导(利福平10 mg/日)使孕激素暴露平均降低15-37%,咪达唑仑暴露平均降低46%。
  • 强CYP3A诱导(利福平600 mg/日)使孕激素暴露平均降低57-90%,咪达唑仑暴露平均降低86%。
  • 弱诱导影响较小,尤其对左炔诺孕酮和炔诺酮产品,或可重新评估口服避孕药推荐。

核心结论

  • 弱CYP3A诱导对孕激素暴露影响较小(平均降低15-37%),强诱导影响显著(平均降低57-90%)。
  • 研究结果提示可能需要重新审视当前口服避孕药(尤其含左炔诺孕酮和炔诺酮产品)的临床推荐。

研究设计与样本

  • 随机临床药物相互作用研究,绝经后女性每治疗组n=12-14例。
  • 固定序列设计:单用受害药物加咪达唑仑、加弱诱导剂利福平10 mg/日、加强诱导剂利福平600 mg/日。
  • 受害药物包括左炔诺孕酮、炔诺酮、去氧孕烯、地诺孕素单方制剂及屈螺酮联合炔雌醇。

主要发现

  • 弱CYP3A诱导(咪达唑仑暴露平均降低46%)使孕激素暴露平均降低15-37%。
  • 强CYP3A诱导(咪达唑仑暴露平均降低86%)使孕激素暴露平均降低57-90%。
  • 对与性激素结合球蛋白结合的药物评估了游离浓度。
  • 诱导效应幅度从弱到强存在差异。

临床怎么用

  • 使用弱CYP3A诱导剂时,孕激素暴露降低幅度相对较小,但避孕效力与暴露的精确关系对多数孕激素尚不明确。
  • 含左炔诺孕酮和炔诺酮的口服避孕药在弱CYP3A诱导剂合用时可能需要重新评估临床推荐。

局限性

  • 对大多数孕激素而言,避孕效力与暴露的精确暴露-反应关系目前尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is known that co-administration of CYP3A inducers may decrease the effectiveness of oral contraceptives containing progestins as mono-preparations or combined with ethinylestradiol. In a randomized clinical drug-drug interaction study, we investigated the effects of CYP3A induction on the pharmacokinetics of commonly used progestins and ethinylestradiol. Rifampicin was used to induce CYP3A. The progestins chosen as victim drugs were levonorgestrel, norethindrone, desogestrel, and dienogest as mono-products, and drospirenone combined with ethinylestradiol. Postmenopausal women (n = 12-14 per treatment group) received, in fixed sequence, a single dose of the victim drug plus midazolam without rifampicin, with rifampicin 10 mg/day (weak induction), and with rifampicin 600 mg/day (strong induction). The effects on progestin exposure were compared with the effects on midazolam exposure (as a benchmark). Unbound concentrations were evaluated for drugs binding to sex hormone binding globulin. Weak CYP3A induction, as confirmed by a mean decrease in midazolam exposure by 46%, resulted in minor changes in progestin exposure (mean decreases: 15-37%). Strong CYP3A induction, in contrast, resulted in mean decreases by 57-90% (mean decrease in midazolam exposure: 86%). Namely, the magnitude of the observed induction effects varied from weak to strong. Our data might provide an impetus to revisit the currently applied clinical recommendations for oral contraceptives, especially for levonorgestrel and norethindrone-containing products, and they might give an indication as to which progestin could be used, if requested, by women taking weak CYP3A inducers-although it is acknowledged that the exact exposure-response relationship for contraceptive efficacy is currently unclear for most progestins.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wiesinger H, Klein S, Rottmann A, et al. The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam. Clin Pharmacol Ther. 2020. PMID: 32275771. doi:10.1002/cpt.1848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。